Immunome Inc
IMNMHealthcare|Biotechnology|USA
$23.35
-0.82 (-3.39%)
Tangible Book
$5.20
Financials
Financial Snapshot
Market Cap
$2.64B
Enterprise Value
$579.0M
Revenue (TTM)
$4.0M
Net Income (TTM)
$-224.6M
Cash & Equivalents
—
Net Cash/Share
$4.87
Free Cash Flow (TTM)
$-214.5M
Operating CF (TTM)
$-196.5M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$49.1M
Monthly Burn
$16.4M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $1.6M | $2.5M | $39.8M | $49.2M | $20.3M | $138.1M | $217.3M | $653.5M | $582.7M | |
| Operating Cash Flow | $-7.4M | $-9.6M | $-12.1M | $-18.2M | $-28.7M | $-7.6M | $-110.8M | $-190.9M | $-196.5M | |
| Free Cash Flow | $-7.6M | $-9.8M | $-12.7M | $-18.3M | $-28.9M | $-8.4M | $-164.3M | $-206.8M | $-214.5M | |
| Capital Expenditure | $-228.0K | $-233.0K | $-586.0K | $-79.0K | $-248.0K | $-831.0K | $-53.5M | $-15.9M | $-18.0M | |
| Financing Cash Flow | $-551.0K | $10.8M | $49.9M | $27.8M | $32.0K | $116.4M | $240.5M | $640.4M | $478.0M |
R&D Spending
R&D (TTM)
$196.8M
R&D Intensity
4901.5%
R&D Growth YoY
+5.1%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.0M | $9.0M | $6.9M | $4.0M | |
| R&D Expense | $6.9M | $8.8M | $7.5M | $14.1M | $23.3M | $103.9M | $281.9M | $187.3M | $196.8M | |
| R&D % of Revenue | — | — | — | — | — | 741.1% | 3117.9% | 2698.3% | 4901.5% | |
| SG&A | $866.0K | $1.5M | $4.8M | $11.1M | $13.6M | $19.7M | $33.0M | $43.8M | $46.0M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.0M | $9.0M | $6.9M | $4.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $14.0M | $9.0M | $6.9M | $4.0M | |
| R&D | $6.9M | $8.8M | $7.5M | $14.1M | $23.3M | $103.9M | $281.9M | $187.3M | $196.8M | |
| SG&A | $866.0K | $1.5M | $4.8M | $11.1M | $13.6M | $19.7M | $33.0M | $43.8M | $46.0M | |
| Operating Income | $-7.7M | $-10.3M | $-12.3M | $-25.2M | $-36.9M | $-109.5M | $-305.8M | $-224.1M | $-238.8M | |
| Interest Expense | $-141.0K | $-106.0K | $-38.0K | $-10.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-7.8M | $-10.4M | $-17.8M | $-24.7M | $-36.9M | $-106.8M | $-293.0M | $-212.4M | $-224.6M | |
| Net Income | $-7.8M | $-10.4M | $-17.8M | $-24.7M | $-36.9M | $-106.8M | $-293.0M | $-212.4M | $-224.6M | |
| EPS (Diluted) | -1.79 | -1.82 | -5.26 | -2.14 | -3.09 | -5.38 | -5.00 | -2.43 | -2.38 | |
| EBITDA | $-7.2M | $-9.7M | $-17.0M | $-24.4M | $-36.3M | $-108.8M | $-303.7M | $-221.2M | $-235.8M | |
| Shares Out. (M) | 4.39 | 5.74 | 3.39 | 11.54 | 12.13 | 19.84 | 58.64 | 87.35 | 113.14 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $2.5M | $39.8M | $49.2M | $20.3M | $98.7M | $143.4M | $653.5M | $582.7M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $39.5M | $74.0M | $0.00 | $0.00 | |
| Total Current Assets | $2.1M | $3.1M | $42.9M | $56.6M | $22.6M | $144.7M | $221.3M | $660.8M | $594.3M | |
| Total Assets | $4.4M | $5.1M | $44.5M | $57.9M | $24.0M | $148.5M | $240.2M | $683.2M | $619.8M | |
| Total Current Liabilities | $1.6M | $1.7M | $3.0M | $9.7M | $7.3M | $21.8M | $54.3M | $45.0M | $27.4M | |
| Long-Term Debt | $325.0K | $113.0K | $134.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $29.7M | $40.7M | $3.2M | $9.7M | $7.4M | $28.7M | $59.1M | $48.8M | $31.1M | |
| Stockholders' Equity | $-25.2M | $-35.6M | $41.3M | $48.2M | $16.7M | $119.9M | $181.2M | $634.3M | $588.7M | |
| Retained Earnings | $-26.1M | $-36.6M | $-54.4M | $-79.1M | $-116.0M | $-222.8M | $-515.8M | $-728.2M | $-782.0M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-7.4M | $-9.6M | $-12.1M | $-18.2M | $-28.7M | $-7.6M | $-110.8M | $-190.9M | $-196.5M | |
| Capital Expenditure | $-228.0K | $-233.0K | $-586.0K | $-79.0K | $-248.0K | $-831.0K | $-53.5M | $-15.9M | $-18.0M | |
| Free Cash Flow | $-7.6M | $-9.8M | $-12.7M | $-18.3M | $-28.9M | $-8.4M | $-164.3M | $-206.8M | $-214.5M | |
| Investing Cash Flow | $-228.0K | $-233.0K | $-586.0K | $-79.0K | $-248.0K | $-30.5M | $-85.1M | $60.8M | $43.7M | |
| Financing Cash Flow | $-551.0K | $10.8M | $49.9M | $27.8M | $32.0K | $116.4M | $240.5M | $640.4M | $478.0M | |
| Issuance of Stock | $0.00 | $0.00 | $44.9M | $27.2M | $0.00 | $125.0M | $250.0M | $678.9M | $506.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $6.8M | $500.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-551.0K | $-612.0K | $-451.0K | $-113.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $11.0K | $14.0K | $621.0K | $3.4M | $5.3M | $6.2M | $15.7M | $25.7M | $27.9M | |
| Net Change in Cash | $-8.2M | $941.0K | $37.2M | $9.5M | $-28.9M | $78.4M | $44.7M | $510.2M | $325.2M |
Dilution Tracker
Shares outstanding grew 880.5% over 5 years — significant dilution
Shares Outstanding
113M
5-Year Share Growth
+880.5%
Stock Issuance (TTM)
$506.4M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 4.39 | 5.74 | 3.39 | 11.54 | 12.13 | 19.84 | 58.64 | 87.35 | 113.14 | |
| YoY Change % | — | 30.8% | -41.0% | 240.4% | 5.1% | 63.6% | 195.5% | 49.0% | 29.5% | |
| Stock Issuance | $0.00 | $0.00 | $44.9M | $27.2M | $0.00 | $125.0M | $250.0M | $678.9M | $506.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $11.0K | $14.0K | $621.0K | $3.4M | $5.3M | $6.2M | $15.7M | $25.7M | $27.9M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -781.4% | -3382.4% | -3228.8% | -5947.9% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -761.9% | -3240.4% | -3060.0% | -5593.9% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -776.2% | -3359.1% | -3186.3% | -5873.6% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -59.9% | -1817.3% | -2980.1% | -5343.4% | |
| ROE % | 0.0% | 0.0% | -624.2% | -55.2% | -113.8% | -156.5% | -194.6% | -52.1% | -54.4% | |
| ROA % | -176.4% | -219.7% | -71.9% | -48.2% | -90.0% | -123.8% | -150.7% | -46.0% | -50.1% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S507.61
Historical9.03 / 49.69 / 535.43
Industry Med.9.49
P/B4.49
Historical1.68 / 3.92 / 21.49
Industry Med.2.93
EV/EBITDA-8.76
Historical-9.36 / -2.00 / -0.08
Industry Med.13.02
EV/Revenue514.42
Historical0.17 / 45.56 / 549.83
Industry Med.8.59
P/FCF—
Historical20.73 / 40.32 / 73.54
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$5.20
Net Current Assets
$4.980
Net-Net Working Capital
$4.87
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | 15.16 | 68.96 | 271.90 | 507.61 | |
| PB Ratio | 0.00 | 0.00 | 2.49 | 3.26 | 1.61 | 3.86 | 3.78 | 3.83 | 4.49 | |
| EV/EBITDA | 0.00 | 0.00 | -3.74 | -4.42 | -0.19 | -3.00 | -1.55 | -8.05 | -8.76 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.28 | 52.22 | 256.51 | 514.42 |
Analyst Estimates & Quality
Altman Z-Score
49.15
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
-3.60
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $2.72M | $60.23M | $219.82M |
| Net Income | $-244.17M | $-259.06M | $-138.85M |
| EPS | -2.16 | -2.18 | -1.24 |
| Book Value per Share | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow per Share | -1.71 | -1.57 | 0.00 |
| Operating CF | $-193.46M | $-177.63M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Development of targeted oncology therapies | $6.9M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $6.9M |